215 related articles for article (PubMed ID: 24833102)
1. Analysis of IGF and IGFBP as prognostic serum biomarkers for adrenocortical carcinoma.
Patel D; Ellis R; Howard B; Boufraqech M; Gara SK; Zhang L; Quezado MM; Nilubol N; Kebebew E
Ann Surg Oncol; 2014 Oct; 21(11):3541-7. PubMed ID: 24833102
[TBL] [Abstract][Full Text] [Related]
2. Circulating IGF system and treatment outcome in epithelial ovarian cancer.
Huang YF; Cheng WF; Wu YP; Cheng YM; Hsu KF; Chou CY
Endocr Relat Cancer; 2014 Apr; 21(2):217-29. PubMed ID: 24273235
[TBL] [Abstract][Full Text] [Related]
3. IGF-I, IGF-II, IGFBP2, IGFBP3 and acid-labile subunit (ALS) in colorectal cancer patients before surgery and during one year follow up in relation to age.
Sztefko K; Hodorowicz-Zaniewska D; Popiela T; Richter P
Adv Med Sci; 2009; 54(1):51-8. PubMed ID: 19482725
[TBL] [Abstract][Full Text] [Related]
4. Elevated free IGF2 levels in localized, early-stage breast cancer in women.
Espelund U; Cold S; Frystyk J; Ørskov H; Flyvbjerg A
Eur J Endocrinol; 2008 Nov; 159(5):595-601. PubMed ID: 18719053
[TBL] [Abstract][Full Text] [Related]
5. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence.
Yu H; Nicar MR; Shi R; Berkel HJ; Nam R; Trachtenberg J; Diamandis EP
Urology; 2001 Mar; 57(3):471-5. PubMed ID: 11248622
[TBL] [Abstract][Full Text] [Related]
6. Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma.
Gao Y; Katki H; Graubard B; Pollak M; Martin M; Tao Y; Schoen RE; Church T; Hayes RB; Greene MH; Berndt SI
Int J Cancer; 2012 Jul; 131(2):E105-13. PubMed ID: 21932422
[TBL] [Abstract][Full Text] [Related]
7. Is there a role for the IGF system and epidermal growth factor (EGF) in the pathogenesis of adrenocortical adenomas? A preliminary case-control study.
Lazúrová I; Jochmanová I; Sotak Š; Špaková I; Mareková M
Physiol Res; 2020 Dec; 69(6):1085-1094. PubMed ID: 33210933
[TBL] [Abstract][Full Text] [Related]
8. The diagnosis of severe growth hormone deficiency in elderly patients with hypothalamic-pituitary disease.
Toogood AA; Jones J; O'Neill PA; Thorner MO; Shalet SM
Clin Endocrinol (Oxf); 1998 May; 48(5):569-76. PubMed ID: 9666868
[TBL] [Abstract][Full Text] [Related]
9. Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure.
Frystyk J; Ivarsen P; Skjaerbaek C; Flyvbjerg A; Pedersen EB; Orskov H
Kidney Int; 1999 Dec; 56(6):2076-84. PubMed ID: 10594783
[TBL] [Abstract][Full Text] [Related]
10. Preoperative serum levels of insulin-like growth factor-binding protein 2 predict prognosis of gastric cancer patients.
Hur H; Yu EJ; Ham IH; Jin HJ; Lee D
Oncotarget; 2017 Feb; 8(7):10994-11003. PubMed ID: 28036255
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of plasma insulin-like growth factor binding protein-2 as a marker for adrenocortical tumors.
Boulle N; Baudin E; Gicquel C; Logié A; Bertherat J; Penfornis A; Bertagna X; Luton JP; Schlumberger M; Le Bouc Y
Eur J Endocrinol; 2001 Jan; 144(1):29-36. PubMed ID: 11174834
[TBL] [Abstract][Full Text] [Related]
12. The differential regulation of the circulating levels of the insulin-like growth factors and their binding proteins (IGFBP) 1, 2 and 3 after elective abdominal surgery.
Cotterill AM; Mendel P; Holly JM; Timmins AG; Camacho-Hübner C; Hughes SC; Ross RM; Blum WF; Langford RM
Clin Endocrinol (Oxf); 1996 Jan; 44(1):91-101. PubMed ID: 8706300
[TBL] [Abstract][Full Text] [Related]
13. Insulin-Like Growth Factor and SLC12A7 Dysregulation: A Novel Signaling Hallmark of Non-Functional Adrenocortical Carcinoma.
Brown TC; Nicolson NG; Stenman A; Juhlin CC; Gibson CE; Callender GG; Korah R; Carling T
J Am Coll Surg; 2019 Sep; 229(3):305-315. PubMed ID: 31034883
[TBL] [Abstract][Full Text] [Related]
14. Insulin-Like Growth Factors (IGF) and IGF-Binding Proteins (IGFBP) in the Serum of Patients with Ovarian Tumors.
Gershtein ES; Isaeva ER; Kushlinsky DN; Korotkova EA; Ermilova VD; Laktionov KP; Adamyan LV
Bull Exp Biol Med; 2016 Apr; 160(6):814-6. PubMed ID: 27165066
[TBL] [Abstract][Full Text] [Related]
15. The insulin-like growth factor family and breast cancer prognosis: A prospective cohort study among postmenopausal women in Denmark.
Kalledsøe L; Dragsted LO; Hansen L; Kyrø C; Grønbæk H; Tjønneland A; Olsen A
Growth Horm IGF Res; 2019 Feb; 44():33-42. PubMed ID: 30622040
[TBL] [Abstract][Full Text] [Related]
16. Serum inhibin pro-αC is a tumor marker for adrenocortical carcinomas.
Hofland J; Feelders RA; van der Wal R; Kerstens MN; Haak HR; de Herder WW; de Jong FH
Eur J Endocrinol; 2012 Feb; 166(2):281-9. PubMed ID: 22127493
[TBL] [Abstract][Full Text] [Related]
17. MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors.
Patel D; Boufraqech M; Jain M; Zhang L; He M; Gesuwan K; Gulati N; Nilubol N; Fojo T; Kebebew E
Surgery; 2013 Dec; 154(6):1224-8; discussion 1229. PubMed ID: 24238045
[TBL] [Abstract][Full Text] [Related]
18. Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease.
Krassas GE; Pontikides N; Kaltsas T; Dumas A; Frystyk J; Chen JW; Flyvbjerg A
J Clin Endocrinol Metab; 2003 Jan; 88(1):132-5. PubMed ID: 12519841
[TBL] [Abstract][Full Text] [Related]
19. IGF2 role in adrenocortical carcinoma biology.
Pereira SS; Monteiro MP; Costa MM; Moreira Â; Alves MG; Oliveira PF; Jarak I; Pignatelli D
Endocrine; 2019 Nov; 66(2):326-337. PubMed ID: 31378849
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of adiponectin multimers and the IGF axis in humans with a heterozygote mutation in the tyrosine kinase domain of the insulin receptor gene.
Højlund K; Beck-Nielsen H; Flyvbjerg A; Frystyk J
Eur J Endocrinol; 2012 Mar; 166(3):511-9. PubMed ID: 22189999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
